Abstract
Axolotl larvae were exposed to thalidomide in concentrations of 0.004, 0.04 or 0.2 mg/ml nutrient solution during the following stages (Harrison's stage series) of embryonic development: Series 1: Stage 0–38 or 0–45, Test of activity. Series 2: Stage 2–11, Study of the first cell cleavages. Series 3: Stage 3–37, Study of the growth rate. Series 4: Stage 12–46 and Series 5: Stage 25–46, General teratology study. Series 6: Stage 37–46, Study of limb differentiation. The results revealed a reduction of activity. There was no visible effect of the drug on the first cell cleavages, up to gastrulation, nor on the growth rate. A high frequency of larvae in the thalidomide treated groups showed generalised oedema during different stages of development. The skin in the region of the gills, kidneys and fore limbs was sometimes rough and showed characteristic tremor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
